Antifibrotic properties of relaxin: In vivo mechanism of action in experimental renal tubulointerstitial fibrosis

Endocrinology

Volumn 151, Issue 10, 2010, Pages 4938-4948

  Hewitson, Tim D ^a,b   Ho, Wen Yang ^b   Samuel, Chrishan S ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 4; GELATINASE B; RELAXIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; COLLAGEN; GELATINASE; RLN2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; DRUG MECHANISM; HISTOPATHOLOGY; IN VIVO STUDY; KIDNEY FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL TUBULOINTERSTITIAL FIBROSIS; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; FIBROSIS; HUMAN; KIDNEY DISEASES; KIDNEY TUBULE; METABOLISM; MYOBLAST; PATHOLOGY; URETERAL OBSTRUCTION;

ANIMALS; CELL PROLIFERATION; COLLAGEN; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROSIS; GELATINASES; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; MICE; MICE, INBRED C57BL; MYOBLASTS, SMOOTH MUSCLE; RELAXIN; URETERAL OBSTRUCTION;

EID: 77957281721     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0286     Document Type: Article

References (42)

1. Chevalier RL, Forbes MS, Thornhill BA 2009 Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75:1145-1152
2. Samuel CS, Hewitson TD 2009 Relaxin and the progression of kidney disease. Curr Opin Nephrol Hypertens 18:9-14
3. Bathgate RA, Hsueh AJ, Sherwood OD 2006 Physiology and molecular biology of the relaxin peptide family. In: Neill JD, ed. The physiology of reproduction. New York: Raven Press; 701-790
4. Sherwood OD 2004 Relaxin's physiological roles and other diverse actions. Endocr Rev 25:205-234
5. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, Summers RJ 2004 Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 65:2054-2064
6. Hewitson TD, Mookerjee I, Masterson R, Zhao C, Tregear GW, Becker GJ, Samuel CS 2007 Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 148:660-669
7. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G 2001 Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59:876-882
8. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP 2003 Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol 285:F59-F67
9. Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA, Dunea G 2003 Effect of relaxin in two models of renal mass reduction. Am J Nephrol 23:8-12
10. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, Samuel CS 2005 Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46:412-418
11. Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, Bathgate R, Darby I, Becker GJ 2004 Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 19:544-552
12. Heeg MH, Koziolek MJ, Vasko R, Schaefer L, Sharma K, Müller GA, Strutz F 2005 The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 68:96-109
13. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA, Tregear GW, Samuel CS 2009 Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23:1219-1229
14. Samuel CS, Hewitson TD, Unemori EN, Tang ML 2007 Drugs of the future: the hormone relaxin. Cell Mol Life Sci 64:1539-1557
15. Bani D 2008 Relaxin as a natural agent for vascular health. Vasc Health Risk Manag 4:515-524
16. Chevalier RL 2006 Specific molecular targeting of renal injury in obstructive nephropathy. Kidney Int 70:1200-1201
17. Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H 2005 Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 20:2670-2680
18. Cochrane AL, Kett MM, Samuel CS, Campanale NV, Anderson WP, Hume DA, Little MH, Bertram JF, Ricardo SD 2005 Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol 16:3623-3630
19. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, Parry LJ, Summers RJ, Tang ML, Amento EP, Tregear GW 2003 Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 17:121-123
20. Samuel CS 2009 Determination of collagen content, concentration, and sub-types in kidney tissue. Methods Mol Biol 466:223-235
21. Gobe G 2009 Identification of apoptosis in kidney tissue sections. Methods Mol Biol 466:175-192
22. Lyons RM, Gentry LE, Purchio AF, Moses HL 1990 Mechanism of activation of latent transforming growth factor β1 by plasmin. J Cell Biol 110:1361-1367
23. Woessner Jr JF 1995 Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 248:510-528
24. Jeyabalan A, Kerchner LJ, Fisher MC, McGuane JT, Doty KD, Conrad KP 2006 Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats. J Appl Physiol 100:1955-1963
25. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M 2002 Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61:1684-1695
26. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ 2006 Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69:2029-2036
27. Lee HY, Zhao S, Fields PA, Sherwood OD 2005 The extent to which relaxin promotes proliferation and inhibits apoptosis of cervical epithelial and stromal cells is greatest during late pregnancy in rats. Endocrinology 146:511-518
28. Bonacchi M, Nistri S, Nanni C, Gelsomino S, Pini A, Cinci L, Maiani M, Zecchi-Orlandini S, Lorusso R, Fanti S, Silvertown J, Bani D 2009 Functional and histopathological improvement of the postinfarcted rat heart upon myoblast cell grafting and relaxin therapy. J Cell Mol Med 13:3437-3448
29. Hughes J, Brown P, Shankland SJ 1999 Cyclin kinase inhibitor p21CIP1/WAF1 limits interstitial cell proliferation following ureteric obstruction. Am J Physiol 277:F948-F956
30. Darby IA, Hewitson TD 2007 Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 257:143-179
31. Ronco P, Lelongt B, Piedagnel R, Chatziantoniou C 2007 Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin Nephrol 27:352-362
32. Ho TY, Yan W, Bagnell CA 2007 Relaxin-induced matrix metalloproteinase- 9 expression is associated with activation of the NF-κB pathway in human THP-1 cells. J Leukoc Biol 81:1303-1310
33. Kapila S 2003 Does the relaxin, estrogen and matrix metalloproteinase axis contribute to degradation of TMJ fibrocartilage? J Musculoskelet Neuronal Interact 3:401-405; discussion 406-407
34. Wick W, Platten M, Weller M 2001 Glioma cell invasion: regulation of metalloproteinase activity by TGF-β. J Neurooncol 53:177-185
35. Olaso E, Ikeda K, Eng FJ, Xu L, Wang LH, Lin HC, Friedman SL 2001 DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 108:1369-1378
36. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP 2003 Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93:1249-1257
37. Schrijvers BF, Flyvbjerg A, De Vriese AS 2004 The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65:2003-2017
38. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, Johnson RJ 2001 Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 37:601-611 (Pubitemid 32195301)
39. Ohashi R, Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N 2002 Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 13:1795-1805
40. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ 2001 Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12:1448-1457
41. Bascands JL, Schanstra JP 2005 Obstructive nephropathy: Insights from genetically engineered animals. Kidney Int 68:925-937
42. Fu P, Liu F, Su S, Wang W, Huang XR, Entman ML, Schwartz RJ, Wei L, Lan HY 2006 Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 17:3105-3114